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Abstract 
Purpose: To investigate the effect of dimedone pyrone (DP) on podocytes in rats with diabetic 
nephropathy (DN).  
Methods: The rats were randomly assigned into 5 experimental groups (n = 10), viz, non-diabetic 
control with no treatment (ND/NT), diabetic with no treatment (DG/NT), diabetic treated with 5 mg/kg 
dimedone pyrone (DG/DP 5), diabetic treated with 10 mg/kg dimedone pyrone (DG/DP 10) and diabetic 
treated with 20 mg/kk dimedone pyrone (DG/DP 20) group. Clinical parameters, including 24 h urinary 
protein, blood urea nitrogen (BUN), serum creatinine (SCR), blood glucose (GLU), and kidney weight 
(KW)/body weight (BW) were determined after 12 weeks of treatment. Hematoxylin and eosin staining 
was used to examine renal pathological changes while transmission electron microscopy (TEM) was 
employed for evaluation of structural changes in the podocytes. The expression levels of nephrin and 
podocin were evaluated using immunofluorescence staining.  
Results: Dimedone pyrone caused a significant decrease in SCR, BUN, GLU, KW/BW and 24 h urine 
protein in DG/DP 20 group compared to DG/NT group. Furthermore, incidences of glomerular disorders, 
chronic tubulo-interstitial damage and glomerular podocyte lesions decreased significantly following 
dimedone pyrone treatment. Glomeruli, tubules and podocytes exhibited pathomorphological 
improvements while nephrin and podocin protein expression levels were significantly higher in the 
nephridial tissue. Decrease in relative kidney weight (KW/BW) and 24 h urinary protein level were 
improved significantly on treatment with dimedone pyrone. Moreover, glomerular disorder, chronic 
tubulo-interstitial damage and glomerular podocyte lesions were also suppressed. The improvement 
was more significant in DG/DP 20 compared to DG/DP 5 and DG/DP 10 groups.  
Conclusion: Dimedone pyrone exhibits a protective effect on the podocytes of rats and may be of 
therapeutic importance in the treatment of diabetic nephropathy. 
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Diabetic nephropathy (DN) is the main cause of 
end-stage renal disease (ESRD) and the disease 
is expected to increase in the coming years [1,2]. 
More than 30 % of all diabetic patients develop 
diabetic nephropathy (DN) [3], which is the most 
frequent cause of chronic kidney disease (CKD) 
and risk factor for stroke and heart attack [4]. The 
number of diabetic patients and those affected by 
DN is rapidly increasing [5]. Not all diabetic 
patients develop DN and the development and 
severity of DN vary greatly from one patient to 
another with familial clustering, suggesting that 
genetic factors play an important role [6].  
 
The expensiveness of renal replacement therapy 
makes it unaffordable even for developed 
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countries [7]. Diabetic nephropathy also leads to 
glomerulosclerosis and ESRD worldwide in its 
advanced stage [8,9]. DN manifests as a clinical 
syndrome that is composed of albuminuria, 
progressively declining glomerular filtration rate 
(GFR) and increased risk for cardiovascular 
disease [10,11]. Persistent proteinuria is the hall-
mark of diabetic nephropathy which is the 
leading cause of end-stage renal disease. 
Furthermore, a reduction in proteinuria is 
associated with a slowing of both the decline in 
the GFR and the progression to ESRD. As a 
result, a reduction in proteinuria has been widely 
used as a surrogate end point for reno-
protection. 
 
Pyrones are reported to exhibit a wide range of 
biological activities which include antimicrobial, 
antimalarial, anti-nematodal activities as well as 
calmodulin-dependent, estrogenic and anti-
estrogenic, and acetylcholinesterase (AChE) 
inhibitory activities [12-14]. In the present study 
the effect of dimedone pyrone (Fig. 1) on 











Fifteen week old male, adult Sprague Dawley 
rats (weighing around 200 g) from Chengdu 
Dashuo Biological Technology Co, Ltd, Chengdu, 
China were maintained in pathogen-free 
conditions and fed irradiated chow. 
 
Reagents and instruments 
 
Dimedone pyrone, TWP, and alloxan were 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Rat urine albumin EIA assay kit, rabbit 
anti-rat nephrin antibodies, rabbit anti-rat podocin 
antibodies and goat anti-rabbit antibodies were 
obtained from Boster (Tarivid; Santen, Osaka, 
Japan). Accu-chek Blood glucose meter from 
Roche Diagnostics GmbH (Tarivid; Santen, 
Osaka, Japan) and 7150 automatic biochemical 
analyzer from Hitachi (BD Biosciences, Franklin 
Lakes, NJ, USA). The JEOL-1230 transmission 
electron microscope was obtained from JEOL 
(BD Biosciences, Franklin Lakes, NJ, USA), 
Vanox multifunctional microscope was 
purchased from Olympus (BD Biosciences, 
Franklin Lakes, NJ, USA) and SDS-PAGE 
electrophoresis was obtained from Bio-Rad 
(Hercules, CA, USA). 
 
Grouping and drug administration 
 
After 15 days of acclimatization to laboratory 
environment, the rats were fasted 12 h prior to 
the experiment. Rats were randomly assigned 
into 5 experimental groups, with 10 animals 
each, as follows: Non-diabetic control (ND/NT) 
group consisting of normal rats without any 
treatment; Diabetic control (DG/NT) group 
consisting of diabetic rats without any treatment; 
Diabetic (DG/DP 5 mg) group consisting of 
diabetic rats treated with dimedone pyrone 5 
mg/kg; Diabetic (DG/DP 10 mg) group consisting 
of diabetic rats treated with 10 mg dimedone /kg 
body weight and Diabetic (DG/DP 20 mg/kg) 
group consisting of diabetic rats treated with 
dimedone pyrone 20 mg/kg.  The dimedone 
pyrone was administered intraperitoneally to the 
rats. During fasting alloxan was injected through 
tail veins at a dose of 42 mg/kg of body weight to 
four animal groups and 72 h latter blood samples 
were collected to measure blood glucose 
concentrations. The blood glucose in rats was 
maintained ≥16.7 mmol/L. The rats were 
weighed weekly to adjust the dose and dimedone 
pyrone was continuously administered for 12 
weeks. During the experiment, the rats were fed 
a standard diet and were free to drink water. Use 
of laboratory animals was approved by the Local 
Committee on Animal Use and Protection and 
performed in accordance with the National 





On the last day of experiment urine was collected 
for 24 h, centrifuged and stored at 80 oC. 
Through right common carotid artery blood 
samples were collected half of the samples were 
put in anticoagulant tubes and the rest was 
centrifuged. The plasma was stored at 20 oC. 
Weight of the animals was also recorded. The 
animals were anaesthetized and after sacrifice, 
kidney tissues were fixed in 4 % 
paraformaldehyde solution and embedded in 
paraffin. The paraffin-embedded kidney tissues 
were cut into 3 μm thick sections. For 
immunofluorescence examination the sections 
were treated with polylysine whereas for 
transmission electron microscopic studies 1 mm 
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sections were put in ethanol at 4 oC for 2 h 
before examination.  
 
Analysis of biochemical parameters 
 
Rat urine albumin EIA assay kit was used for 24 
h urinary protein concentration determination as 
per the manufacturer's instructions. Clinical 
parameters like body weight, feed intake, water 
intake, and diuresis were recorded for every 
individual metabolic cage. The biochemical 
parameters including serum creatinine (SCR), 
blood urea nitrogen (BUN), aspartate 
aminotransferase (AST) and alanine 
aminotransferase (ALT) were detected in the 
serum using a 7150 automatic biochemical 
analyzer. Johnson & Johnson’s standard 
enzymatic method was used for blood glucose 
determination. 
 
Examination of renal tissue under light 
microscopy 
 
Two mm sections of left kidney were fixed in 10 
% formaldehyde and embedded in paraffin. The 
paraffin embedded sections were cut into 1 μm 
thick sections and after de-paraffinization were 
stained with hematoxylin and eosin (HE). The 





For examination of ultrastructural changes tissue 
specimens were cut into sections and washed in 
phosphate buffer followed by post fixation in 
glutaraldehyde. The tissues, after dehydration in 
graded acetone concentrations, were embedded 
in Araldite, cut into very thin sections, stained 
with uranyl acetate and aluminium citrate for 
examination under a JEOL 1230 transmission 
electron microscope. 
 
Distribution of nephrin and podocin 
 
The paraffin embedded tissues were cut into 1 
mm thin sections, de-paraffinized and incubated 
overnight with rabbit anti rat nephrin (1:400) and 
rabbit anti rat podocin (1:400) antibodies at 4 oC. 
After washing in phosphate buffer the slices were 
treated with fluorescein isothiocyanate labeled 





All the results are expressed as mean ± standard 
deviation (SD). SPSS 11.0 software package 
(SPSS, Inc, Chicago, IL, USA) was used for 
statistical analysis of the data. Differences were 




Effect of dimedone pyrone on proteinuria in 
rats with DN 
 
Examination of 24 h proteinuria in all the five 
groups of animals revealed a significantly higher 
level in DG/NT group compared to that in ND/NT 
and DG/DP 20 groups (Fig. 2). The 24 h 
proteinuria in DG/DP 10 group was lower than 
DG/VT 5 group which in turn showed the level 




Fig. 2: The 24 h urine protein level comparison of non-
diabetic, diabetic and dimedone pyrone treated 
diabetic rats 
 
Effect of dimedone pyrone on kidney 
weight/body weight (KW/BW) in DN 
 
After 12 weeks of treatment it was observed that 
compared to ND/NT group, the KW/BW ratios in 
DG/NT group was higher (p < 0.01) and that in 
DG/DP 20 group was significantly lower (Fig. 3). 
However the KW/BW ratio in DG/DP 5 group was 




Fig. 3: Relative kidney weight (KW/BW ratios) 
comparison of non-diabetic, diabetic and dimedone 
pyrone treated diabetic rats 
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Effect of dimedone pyrone on serum 
biochemistry parameters of DN rats 
 
In DG/NT group the SCR, BUN and fasting 
glucose levels were significantly higher (p < 0.05) 
compared to ND/NT group (Table 1). 
 
Change of renal tissue pathology of DN 
 
In DG/NT group the HE stained renal biopsy 
samples exhibited tubular deformation and 
glomerular hypertrophy. However dimedone 
pyrone treated animals showed a marked 
decrease in tubular deformation and glomerular 
hypertrophy on treatment with 20 mg/kg body 
weight of dimedone pyrone after 12 weeks (Fig 
4). 
 
Effect of podocyte disease on DN rats 
 
Compared to NG/NT group, the animals in 
DG/NT group showed abnormal morphological 
appearance of podocytes like fusion and 
decrease in foot processes. Treatment with 
dimedone pyrone caused a reversal of alloxan 
induced effect on podocytes. Although the 
reversal of effect started at a concentration of 5 
mg/kg body weight but was significant at 20 
mg/kg in DG/DP 20 group (Fig. 5). 
 
 




BUN(mmol/L) SCr(μmol/L) AST (U/L) ALT (U/L) 
ND/NT 5.02 ± 0.56 5.98 ± 0.67 66.90 ± 4.88 58.23 ± 8.75 53.65 ± 6.59 
DG/NT 25.14 ± 3.83 11.26 ± 1.86 95.57 ± 10.76 70.43 ± 8.46 78.79 ± 2.53 
DG/DP 5 23.23 ± 2.78 10.67 ± 1.48 91.23 ± 10.43 68.65 ± 7.98 70.23 ± 5.11 
DG/DP 10 18.02 ± 1.98 8.27 ± 1.74 74.12 ± 10.27 63.42 ± 8.12 61.67 ± 7.65 
DG/DP 20 6.45 ± 1.06 6.91 ± 1.58 68.51 ± 10.96 59.84 ± 7.93 54.78 ± 6.43 
The results are mean ± SD. Key: Glu, glucose; BUN, blood urea nitrogen; Cr, creatinine; AST, aspartate 




Fig 4: Renal pathological changes in control and dimedone pyrone-treated DN rats ND/NT, non-diabetic control 
no treatment; DG/NT, diabetic no treatment, DG/DP 5, diabetic group treated with 5 mg/kg dimedone pyrone 
treated and DG/DP 10, diabetic group treated with 10 mg/kg dimedone pyrone and DG/DP 20, diabetic group 
treated with 20 mg/kg dimedone purone 
Luan & Sun 





Fig 5: Podocyte lesions using electron microscopy in DN rats. ND/NT, non-diabetic control no treatment; DG/NT, 
diabetic no treatment, DG/DP 5, diabetic group treated with 5 mg/kg dimedone pyrone treated and DG/DP 10, 
diabetic group treated with 10 mg/kg dimedone pyrone and DG/DP 20, diabetic group treated with 20 mg/kg 
dimedone purone 
 




Fig 6: Expression of nephrin and podocin proteins in 
podocytes of DN rats. ND/NT, non-diabetic control no 
treatment; DG/NT, diabetic no treatment, DG/DP 5, 
diabetic group treated with 5 mg/kg dimedone pyrone 
treated and DG/DP 10, diabetic group treated with 10 
mg/kg dimedone pyrone and DG/DP 20, diabetic 
group treated with 20 mg/kg dimedone purone 
 
In DG/NT group of rats, nephrin and podocin 
protein expression levels were significantly low 
compared to NG/NT group. Treatment with 
dimedone pyrone increased the level of nephrin 
and podocin protein expression. The increase in 
expression was significant and comparable to 
that of NG/NT group at a concentration of 20 




It is reported that proteinuria on accumulation in 
mesangial cells enhances glomerular sclerosis 
[15,16]. Urinary proteins also regulate tubular cell 
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function, which changes the growth 
characteristics of cytokines and matrix proteins, 
as well as their phenotypic expression and 
induction of fibrosis [17]. The present study 
demonstrates that dimedone pyrone decreases 
the level of proteinuria in the DN rats. 
 
Changed podocyte ultrastructure and associated 
molecules induce DN proteinuria [18,19]. Micro-
albuminuria in DN decreases podocyte count 
which leads to compensatory hypertrophy to 
cover basement membrane, thereby increasing 
permeability. These changes produce abundant 
proteinuria and subsequently increase podocyte 
injury. Detachment of podocytes exposes the 
basement membrane and damage fenestrated 
membrane and allows large number of proteins 
to pass [14]. This ultimately leads to glomerular 
sclerosis and progressive loss of renal function 
[20]. The results from our study showed that 
dimedone pyrone at a concentration of 20 mg/kg 
body weight in rats reversed the effect of 
damage caused to podocytes in DN rats. 
 
Slit diaphragm (SD) is the main barrier which 
filters protein macromolecules and is composed 
of neph 1, nephrin, podocin and FAT1 [21]. In 
animal experiments, researchers have found that 
DM worsens kidney damage in rats, reduces 
nephrin expression and increases albuminuria in 
urine [22]. The decreased expression of nephrin 
preceded glomerular tissue damage and is an 
early event in DN. In the DN model, changes in 
podocin were associated with protein and mRNA 
expression levels of nephrin [23]. 
 
We observed that dimedone pyrone treatment 
decreased glomerular hypertrophy and tubular 
deformation in DN rats after 12 weeks. There 
was also a decrease in fusion of the podocyte 
foot processes, disappearance of membrane slits 
and reduced number of slits in DG/DP group of 
rats. Dimedone pyrone also increased the 
expression level of nephrin and podocin in 
DG/DP 5 and DG/DP 10 groups. However, the 




Dimedone pyrone exhibits a protective effect on 
the podocytes of rats and can be of therapeutic 
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